Classified in: Health, Science and technology
Subjects: Conference, Webcast, Advisory

FogPharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

FogPharma^®, a clinical-stage precision medicine biopharmaceutical company committed to transforming the lives of patients facing devastating diseases through the discovery of life changing and lifesaving therapeutics using its Helicontm peptide platform, today announced that Mathai Mammen, M.D., Ph.D., chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:30 p.m. Pacific Time. In addition, Dr. Mammen will participate in the opening keynote panel "State of Innovation 2024" at the WuXi Global Forum 2024 on the same day at 1:30 p.m. Pacific Time.

Additional information about FogPharma can be found on the company's website at www.fogpharma.com.

About FogPharma^®

FogPharma is a clinical-stage biopharmaceutical company that seamlessly integrates breakthroughs in bench science and data science to create transformative precision therapeutics for patients suffering from devastating and often fatal diseases such as cancer. FogPharma's discovery engine creates Helicontm therapeutics, which are a new generation of ultra-diverse, highly tunable peptide drugs capable of modulating virtually any protein implicated in disease. Our robust and wholly owned pipeline of programs is currently focused on cancer targets that are intractable to small molecules and biotherapeutics. The company's lead program, FOG-001, is a long sought-after blocker of ?-catenin:TCF interactions that is currently being evaluated in a Phase 1/2 clinical trial in patients with Wnt/?-catenin signaling pathway-activated solid tumors, including colorectal cancer. FogPharma has raised more than $350 million to date from top investors and is led by an experienced team of industry experts. FogPharma is headquartered in Cambridge, MA. For more information, please visit www.fogpharma.com.

These press releases may also interest you

at 02:30	Pop-R&B Artist & International Award-Winning Classical Pianist Janet Noh Releases Critically Acclaimed 'Oh Child' Record and Film Production. 100% of Proceeds Are Being Donated to the Korean American Family Service Center, Supporting Survivors of Domestic Abuse.
	On April 30th, 2024, in celebration of Mental Health Awareness Month and AAPI Heritage Month, international award-winning classical pianist and pop-R&B singer Janet Noh released her newest record 'Oh Child' as well as its accompanying cinematic...
at 02:05	Epsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company Expansion
	Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer (CBO) and Peter Finan, currently a Non-Executive Director, as Non-Executive...
at 02:00	Novo Holdings commits DKK 1.4 billion (?188 million) to build a quantum technology start-up ecosystem
	With Denmark as the centre of gravity, the ambition is to invest in, support and advance some of the world's most promising quantum technology companies with applications in the life sciences. The quantum industry, which develops novel technologies...
at 01:40	135th Canton Fair Showcases Leading Medical Devices, Elevating Global Health Management
	In a significant move to meet the growing demand for health management solutions, the 135th China Import and Export Fair ("Canton Fair" or "the Fair") has brought together top-tier companies from the Medicines, Health Products and Medical Devices...
at 00:05	New Campaign Brings to Forefront How Preeclampsia Prevention is Possible for Pregnant Women
	As May marks Preeclampsia Awareness Month, leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, "Preeclampsia Prevention is Possible." The campaign elevates awareness of a major paradigm...
30 avr 2024	Clinical Trial Analytics Services Market Projected to Reach $11.95 billion by 2030 - Exclusive Report by 360iResearch
	The report titled "Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization &...
	More news about Health...

News published on 4 january 2024 at 08:10 and distributed by:

FogPharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

These press releases may also interest you

Le Lézard

Others sections

Follow us